Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).
Geographically, North America captured lion’s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.

The global Cardiovascular Drugs market was valued at US$ 6014.9 million in 2019 and is expected to reach US$ 6361.2 million by the end of 2026, growing at a CAGR of 0.8% during 2021-2026.
This report focuses on Cardiovascular Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Cardiovascular Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Cardiovascular Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Renin-Angiotensin System Blockers
Beta Blockers
Diuretics
Anti-Clotting Agents
Antihyperlipidemic

Segment by Application
Hypertension
Hyperlipidemia

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Amgen
AstraZeneca
Bayer
Bristol Myers Squibb and Pfizer
Daiichi Sankyo
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Portola
Sanofi